期刊
HUMAN BRAIN MAPPING
卷 35, 期 9, 页码 4916-4931出版社
WILEY
DOI: 10.1002/hbm.22522
关键词
Alzheimer's disease; arterial spin labeling; classification; diagnostic imaging; frontotemporal dementia; magnetic resonance imaging; presenile dementia; support vector machines
资金
- Erasmus MC grant
- European COST Action Arterial spin labelling Initiative in Dementia (AID) [BM1103]
- Alzheimer's Disease Neuroimaging Initiative (ADNI
- National Institutes of Health) [U01 AG024904]
- National Institute on Aging
- National Institute of Biomedical Imaging and Bioengineering
- Abbott
- Alzheimer's Association
- Alzheimer's Drug Discovery Foundation
- Amorfix Life Sciences
- Astra-Zeneca
- Bayer HealthCare
- BioClinica
- Biogen Idec
- Bristol-Myers Squibb Company
- Eisai
- Elan Pharmaceuticals
- Eli Lilly and Company
- F. Hoffmann-La Roche
- Genentech
- GE Healthcare
- Innogenetics, N.V.
- IXICO
- Janssen Alzheimer Immunotherapy Research & Development, LLC
- Johnson & Johnson Pharmaceutical Research & Development LLC.
- Medpace
- Merck Co.
- Meso Scale Diagnostics, LLC.
- Novartis Pharmaceuticals Corporation
- Pfizer
- Servier
- Synarc
- Takeda Pharmaceutical Company
- Canadian Institutes of Health Research, Canada
- National Institutes of Health
Because hypoperfusion of brain tissue precedes atrophy in dementia, the detection of dementia may be advanced by the use of perfusion information. Such information can be obtained noninvasively with arterial spin labeling (ASL), a relatively new MR technique quantifying cerebral blood flow (CBF). Using ASL and structural MRI, we evaluated diagnostic classification in 32 prospectively included presenile early stage dementia patients and 32 healthy controls. Patients were suspected of Alzheimer's disease (AD) or frontotemporal dementia. Classification was based on CBF as perfusion marker, gray matter (GM) volume as atrophy marker, and their combination. These markers were each examined using six feature extraction methods: a voxel-wise method and a region of interest (ROI)-wise approach using five ROI-sets in the GM. These ROI-sets ranged in number from 72 brain regions to a single ROI for the entire supratentorial brain. Classification was performed with a linear support vector machine classifier. For validation of the classification method on the basis of GM features, a reference dataset from the AD Neuroimaging Initiative database was used consisting of AD patients and healthy controls. In our early stage dementia population, the voxelwise feature-extraction approach achieved more accurate results (area under the curve (AUC) range = 86-91%) than all other approaches (AUC = 57-84%). Used in isolation, CBF quantified with ASL was a good diagnostic marker for dementia. However, our findings indicated only little added diagnostic value when combining ASL with the structural MRI data (AUC = 91%), which did not significantly improve over accuracy of structural MRI atrophy marker by itself. (C) 2014 Wiley Periodicals, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据